Squarepoint
AEGR

Squarepoint’s Aegerion Pharmaceuticals AEGR Stock Holding History

Squarepoint’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-49,900
Closed -$74K – 1454
2016
Q2 		$74K Buy
49,900
+14,994
+43% +$34.3K ﹤0.01% 998
2016
Q1 		$129K Buy
34,906
+2,906
+9% +$18K 0.01% 1053
2015
Q4 		$323K Buy
32,000
+13,602
+74% +$164K 0.04% 769
2015
Q3 		$250K Buy
+18,398
New +$328K 0.06% 306

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Squarepoint's AEGR Position: Q3 2016 in Review

Squarepoint sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2016, closing a stake of 49,900 shares — an estimated $74K sold.

Squarepoint first reported a position in AEGR in Q3 2015 and held it in 4 quarters. The position peaked at $323K in Q4 2015. 58 funds tracked by Wall St. Rank hold AEGR as of Q3 2016.

  • Squarepoint reported no remaining Aegerion Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Squarepoint sold 49,900 Aegerion Pharmaceuticals shares in Q3 2016, an estimated $74K.
  • Squarepoint first reported a position in Aegerion Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Squarepoint's Aegerion Pharmaceuticals position peaked at $323K in Q4 2015.
  • 58 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2016.

Based on Squarepoint's 13F filing for Q3 2016, filed 15 Nov 2016.